Pediatric Disease Registry in Essential Thrombocythaemia (ET)
- Conditions
- Essential Thrombocythemia (ET)
- Registration Number
- NCT01198717
- Lead Sponsor
- Shire
- Brief Summary
The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- 6 years or over and less than 18 years patient has ET according to the WHO criteria as guidance
- Interventional clinical study participation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment effects on platelet count in children ages 6-17 years inclusive. 60 months
- Secondary Outcome Measures
Name Time Method Drug utilization of cytoreductive therapy in children ages 6-17 years inclusive 60 months
Trial Locations
- Locations (32)
Paediatric Clinic University Hospital Olomouc
🇨🇿Olomouc, Czechia
Clinic of Paediatric haematology and oncology University Hospital Motol
🇨🇿Prague, Czechia
Paediatric Oncology Unit, Hopital Cote De Nacre
🇫🇷Caen, France
Practicen Hospitalier , Institute d'Hematologie et Oncologie Pediatrique
🇫🇷Lyon, France
Centre Hospitalier Lyon Sud - service Hématologie
🇫🇷Pierre Benite, France
Hopitaux de Brabois
🇫🇷Vandoeuvre Les Nancy, France
Klinikum Chemnitz GmbH, Klinik für Kinder-und Jugendmedizin
🇩🇪Chemnitz, Germany
Zentrum für Kinder- und Jugendmedizin Klinik II / III
🇩🇪Frankfurt, Germany
"Agia Sophia" Children's Hospital
🇬🇷Athens, Greece
Dipartimento di Biomedicina dell'Eta Evolutiva. University of Bari
🇮🇹Bari, Italy
Scroll for more (22 remaining)Paediatric Clinic University Hospital Olomouc🇨🇿Olomouc, Czechia